Osteosarcoma

Osteosarcoma is the most common primary malignant bone tumour.

It mainly affects children and adolescents during periods of rapid skeletal growth.

Outcomes for localised disease improved with multiagent chemotherapy.

Outcomes for metastatic disease remain poor.

That is the key context here.

In osteosarcoma, lung metastasis drives much of the mortality.

So a compound that affects migration and invasion can be more relevant than one that only shows generic cytotoxicity.

The Urolithin A evidence base is still very early.

It consists of one 2025 in vitro study.

There is no animal-model evidence.

There are no clinical trials.

Overview of the evidence

The first dedicated Urolithin A osteosarcoma paper focused on metastasis biology rather than primary tumour killing.

That was the right choice.

In osteosarcoma, the hardest clinical problem is often pulmonary spread rather than control of the original bone lesion alone.

The study combined:

• network pharmacology

• molecular docking and dynamics simulation

• experimental work in MG-63 osteosarcoma cells

The central result was coherent.

Urolithin A was predicted to target AKT1, EGFR, and MMP9.

In cell work, it reduced migration, invasion, and MMP2 and MMP9 activity.

All of that fits the same metastatic axis.

Why osteosarcoma metastasis is the right target

Standard treatment for localised osteosarcoma still relies on the same broad framework used for decades.

That usually means neoadjuvant chemotherapy, surgery, and postoperative chemotherapy.

The core regimen is often MAP:

• methotrexate

• doxorubicin

• cisplatin

Five-year survival is much better in localised disease than in metastatic disease.

Once lung metastases are present, prognosis worsens sharply.

That is why metastasis suppression matters so much in this cancer type.

Three parts of this biology are especially relevant:

• AKT1 — promotes survival, proliferation, and downstream invasion signalling

• EGFR — activates PI3K and MAPK signalling that supports progression

• MMP2 and MMP9 — degrade extracellular matrix and help tumour cells invade and disseminate

These are not disconnected markers.

They form a plausible pathway.

EGFR can activate PI3K and AKT1.

AKT signalling can drive MMP expression.

MMP2 and MMP9 then help break down matrix barriers needed for metastatic spread.

That makes Urolithin A mechanistically relevant before any wet-lab validation even starts.

Computational target identification

The study first mapped predicted Urolithin A targets against osteosarcoma-related genes.

It then prioritised the strongest overlaps for validation.

The main computational findings were:

• AKT1, EGFR, and MMP9 emerged as the leading hub targets

• docking suggested stable Urolithin A binding to AKT1 and EGFR

• molecular dynamics supported stable target-ligand complexes over time

• TNMplot analysis showed AKT1 is strongly upregulated in osteosarcoma tissue versus normal bone

This gives the study a useful structure.

It does not prove direct target engagement in cells.

But it does show the in vitro experiments were built on a biologically coherent model rather than a blind screen.

Experimental validation in MG-63 cells

The wet-lab work used MG-63 cells.

This is a standard human osteosarcoma line.

It is a reasonable first model because it expresses the same pathways highlighted in the computational phase.

Migration suppression

At 75 µM, Urolithin A significantly reduced MG-63 cell migration in scratch-assay work.

That matters because migration is one of the first steps in metastatic behaviour.

A cell has to detach, move, and navigate surrounding tissue before it can invade more deeply.

Invasion suppression

Urolithin A also significantly reduced invasion in Matrigel transwell assays.

That is the stronger metastatic readout.

It models the ability of cells to cross an extracellular-matrix barrier.

In osteosarcoma, that kind of behaviour is directly relevant to lung dissemination.

Enhanced cell adhesion

The same study reported increased cell adhesion after Urolithin A treatment.

That fits the rest of the story.

Cells that remain more anchored are usually less motile and less invasive.

It is not the most important result on its own.

But it supports the anti-metastatic interpretation.

MMP2 and MMP9 activity reduction

This is the most specific experimental finding.

Gelatin zymography showed that Urolithin A reduced the enzymatic activity of both MMP2 and MMP9.

That matters more than a simple expression readout.

Protein levels do not always reflect functional enzyme activity.

Zymography shows that the matrix-degrading function itself was reduced.

That is exactly the kind of result you want in a metastasis-focused osteosarcoma paper.

Why the MMP result matters clinically

High MMP2 and MMP9 activity is associated with invasive behaviour and poorer prognosis in osteosarcoma.

These enzymes help degrade type IV collagen and other basement-membrane components.

That allows tumour cells to push through tissue barriers and gain vascular access.

So this is not a generic pathway footnote.

It is near the centre of osteosarcoma metastatic biology.

For now, the evidence remains limited to one cell line.

Still, it is functionally relevant evidence.

Bone-biology context

There is also an adjacent bone-microenvironment angle.

Separate non-cancer work suggests Urolithin A can inhibit osteoclast differentiation and reduce osteoclast-mediated bone resorption.

That is not osteosarcoma treatment evidence.

It still matters as context.

Osteosarcoma alters bone remodelling and promotes local bone destruction.

A compound that dampens osteoclastogenesis could, in theory, have supportive relevance within that microenvironment.

That idea remains indirect.

It should not be treated as anti-tumour proof.

Comparison with Urolithin B

A useful parallel comes from Urolithin B.

A 2023 osteosarcoma study reported that Urolithin B reduced proliferation, migration, and invasion and induced G2/M arrest.

It also reduced MMP-2 and MMP-9 expression.

That does not validate Urolithin A directly.

It does strengthen the idea that the wider urolithin class may have real anti-metastatic relevance in osteosarcoma.

The overlap is especially notable at the MMP level.

What remains unknown

Several major gaps still matter.

• only one primary Urolithin A study exists

• only one osteosarcoma cell line was tested

• there is no orthotopic or metastatic animal-model evidence

• there is no combination work with methotrexate, doxorubicin, or cisplatin

• the active concentration used is higher than typical plasma levels seen with standard oral dosing

• it is not known whether bone-tumour tissue exposure could narrow that gap

• it is not known whether Urolithin A affects primary tumour growth in osteosarcoma

• there are no clinical trials in osteosarcoma patients

Bottom line

Osteosarcoma is an early but purposeful Urolithin A evidence area.

The current signal is not about tumour shrinkage.

It is about metastatic behaviour.

That makes sense for this disease.

It also fits the broader Urolithin A pattern of suppressing migration, invasion, and dissemination-related biology seen on the Lung Cancer page.

The strongest current takeaways are:

• Urolithin A was predicted to target the EGFR → AKT1 → MMP invasion axis

• it reduced migration and invasion in MG-63 osteosarcoma cells

• it reduced the functional activity of MMP2 and MMP9

• the whole story is biologically aligned with the main clinical problem in osteosarcoma, which is lung metastasis

The evidence is still very thin.

It rests on one in vitro paper.

Even so, it is a credible first study and one worth tracking.

Evidence level summary

References

Urolithin A suppressed osteosarcoma cell migration and invasion by modulating MMP2 and MMP9 activity through network pharmacology and experimental validation https://pmc.ncbi.nlm.nih.gov/articles/PMC12271505/

Urolithin B inhibits proliferation and migration and promotes apoptosis and necrosis by inducing G2/M arrest and targeting MMP-2 and MMP-9 expression in osteosarcoma https://pubmed.ncbi.nlm.nih.gov/37555500/

Urolithin A attenuates osteoclast differentiation and compensates for bone loss https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1585922/full

Unveiling the potential of Urolithin A in cancer therapy — mechanistic insights to future perspectives https://pmc.ncbi.nlm.nih.gov/articles/PMC12188533/